Hirofumi Mukai

Summary

Affiliation: National Cancer Center
Country: Japan

Publications

  1. doi request reprint Safety and efficacy of a combination of docetaxel and cisplatin in patients with unknown primary cancer
    Hirofumi Mukai
    Division of Oncology and Hematology, National Cancer Center Hospital East, Chiba, Japan
    Am J Clin Oncol 33:32-5. 2010
  2. doi request reprint Phase I dose-escalation and pharmacokinetic study (TED 11576) of cabazitaxel in Japanese patients with castration-resistant prostate cancer
    Hirofumi Mukai
    National Cancer Center Hospital East, 6 5 1 Kashiwanoha Kashiwa shi, Chiba, 277 8577, Japan
    Cancer Chemother Pharmacol 73:703-10. 2014
  3. doi request reprint Prospective Cohort Study: Whether or Not Patients Benefit from Participation Itself in Randomized-controlled Trials (SELECT BC ECO)
    Hirofumi Mukai
    Division of Oncology Hematology, National Cancer Center Hospital East, 6 5 1, Kashiwanoha, Kashiwa shi, Chiba, Japan
    Jpn J Clin Oncol 44:296-9. 2014
  4. doi request reprint Ki-67 index guided selection of preoperative chemotherapy for HER2-positive breast cancer: a randomized phase II trial
    Takeshi Yamaguchi
    Jpn J Clin Oncol 42:1211-4. 2012
  5. doi request reprint Randomized study of taxane versus TS-1 in women with metastatic or recurrent breast cancer (SELECT BC)
    Hirofumi Mukai
    Division of Oncology Hematology, National Cancer Center Hospital East, 6 5 1, Kashiwanoha, Kashiwa shi, Chiba, Japan
    Jpn J Clin Oncol 40:811-4. 2010
  6. doi request reprint Targeted therapy in breast cancer: current status and future directions
    Hirofumi Mukai
    Division of Oncology Hematology, National Cancer Center Hospital East, 6 5 1, Kashiwanoha, Kashiwa shi, Chiba, Japan
    Jpn J Clin Oncol 40:711-6. 2010
  7. doi request reprint Treatment strategy for HER2-positive breast cancer
    Hirofumi Mukai
    Division of Oncology Hematology, National Cancer Center Hospital East, 6 5 1 Kashiwanoha, Kashiwa, Chiba, Japan
    Int J Clin Oncol 15:335-40. 2010
  8. doi request reprint Assessment of different criteria for the pathological complete response (pCR) to primary chemotherapy in breast cancer: standardization is needed
    Hirofumi Mukai
    Division of Oncology Hematology, National Cancer Center Hospital East, 6 5 1, Kashiwanoha, Kashiwa shi, Chiba, Japan
    Breast Cancer Res Treat 113:123-8. 2009
  9. ncbi request reprint An alternative medicine, Agaricus blazei, may have induced severe hepatic dysfunction in cancer patients
    Hirofumi Mukai
    Division of Oncology Hematology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan
    Jpn J Clin Oncol 36:808-10. 2006
  10. doi request reprint Phase I trial of chemoradiotherapy with the combination of S-1 plus cisplatin for patients with unresectable locally advanced squamous cell carcinoma of the head and neck
    Makoto Tahara
    Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Chiba, Japan
    Cancer Sci 102:419-24. 2011

Detail Information

Publications33

  1. doi request reprint Safety and efficacy of a combination of docetaxel and cisplatin in patients with unknown primary cancer
    Hirofumi Mukai
    Division of Oncology and Hematology, National Cancer Center Hospital East, Chiba, Japan
    Am J Clin Oncol 33:32-5. 2010
    ..Evaluation of the safety and efficacy of docetaxel and cisplatin in the treatment of unknown primary cancer...
  2. doi request reprint Phase I dose-escalation and pharmacokinetic study (TED 11576) of cabazitaxel in Japanese patients with castration-resistant prostate cancer
    Hirofumi Mukai
    National Cancer Center Hospital East, 6 5 1 Kashiwanoha Kashiwa shi, Chiba, 277 8577, Japan
    Cancer Chemother Pharmacol 73:703-10. 2014
    ..The purpose of the study is to analyze the pharmacokinetic (PK) profile of cabazitaxel and evaluate its safety and tolerability as a 1-h IV infusion every 3 weeks in Japanese patients with castration-resistant prostate cancer (CRPC)...
  3. doi request reprint Prospective Cohort Study: Whether or Not Patients Benefit from Participation Itself in Randomized-controlled Trials (SELECT BC ECO)
    Hirofumi Mukai
    Division of Oncology Hematology, National Cancer Center Hospital East, 6 5 1, Kashiwanoha, Kashiwa shi, Chiba, Japan
    Jpn J Clin Oncol 44:296-9. 2014
    ..This trial is a hitherto exceptional prospective study and is suitable to clarify the effects of participation per se in such a trial on prognosis when compared with previous two studies. ..
  4. doi request reprint Ki-67 index guided selection of preoperative chemotherapy for HER2-positive breast cancer: a randomized phase II trial
    Takeshi Yamaguchi
    Jpn J Clin Oncol 42:1211-4. 2012
    ..The primary endpoint is the rate of pathological complete response. The secondary endpoints are the objective response rate, disease-free survival and overall survival. Two hundred patients were planned to be accrued...
  5. doi request reprint Randomized study of taxane versus TS-1 in women with metastatic or recurrent breast cancer (SELECT BC)
    Hirofumi Mukai
    Division of Oncology Hematology, National Cancer Center Hospital East, 6 5 1, Kashiwanoha, Kashiwa shi, Chiba, Japan
    Jpn J Clin Oncol 40:811-4. 2010
    ..A threshold hazard ratio of 1.333 will be used to determine whether overall survival in the TS-1 group is equivalent (not inferior) to that in the taxane group. The target number of registered patients is 600...
  6. doi request reprint Targeted therapy in breast cancer: current status and future directions
    Hirofumi Mukai
    Division of Oncology Hematology, National Cancer Center Hospital East, 6 5 1, Kashiwanoha, Kashiwa shi, Chiba, Japan
    Jpn J Clin Oncol 40:711-6. 2010
    ..Oncologists will be required to master appropriate initial therapy to treat them; on the other hand, oncologists need to cooperate with specialists in other fields more than they used to...
  7. doi request reprint Treatment strategy for HER2-positive breast cancer
    Hirofumi Mukai
    Division of Oncology Hematology, National Cancer Center Hospital East, 6 5 1 Kashiwanoha, Kashiwa, Chiba, Japan
    Int J Clin Oncol 15:335-40. 2010
    ..Biomarkers are being aggressively searched for concerning individual drugs under development. A position of the "proper drug for the proper patient" will be more firmly established...
  8. doi request reprint Assessment of different criteria for the pathological complete response (pCR) to primary chemotherapy in breast cancer: standardization is needed
    Hirofumi Mukai
    Division of Oncology Hematology, National Cancer Center Hospital East, 6 5 1, Kashiwanoha, Kashiwa shi, Chiba, Japan
    Breast Cancer Res Treat 113:123-8. 2009
    ..Evaluation and comparison of the pathological complete response (pCR) to this regimen according to various definitions in different clinical trials. Utilize the data to propose standardization of definitions...
  9. ncbi request reprint An alternative medicine, Agaricus blazei, may have induced severe hepatic dysfunction in cancer patients
    Hirofumi Mukai
    Division of Oncology Hematology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan
    Jpn J Clin Oncol 36:808-10. 2006
    ..It is necessary to evaluate many modes of complementary and alternative medicines, including the Agaricus blazei extract, in rigorous, scientifically designed and peer-reviewed clinical trials...
  10. doi request reprint Phase I trial of chemoradiotherapy with the combination of S-1 plus cisplatin for patients with unresectable locally advanced squamous cell carcinoma of the head and neck
    Makoto Tahara
    Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Chiba, Japan
    Cancer Sci 102:419-24. 2011
    ..Administration of S-1 as a suspension or by whole capsule can be considered therapeutically interchangeable. Although these data are preliminary, activity was highly promising, and this approach warrants further investigation...
  11. doi request reprint First experience of active surveillance before systemic target therapy in patients with metastatic renal cell carcinoma
    Nobuaki Matsubara
    Division of Oncology and Hematology, National Cancer Center Hospital East, Chiba, Japan
    Urology 82:118-23. 2013
    ..To reveal the outcomes of initial active surveillance (AS), followed by deferred systemic target therapy, in a subpopulation of patients with indolent metastatic renal cell carcinoma (mRCC)...
  12. doi request reprint Different prognostic significance of Ki-67 change between pre- and post-neoadjuvant chemotherapy in various subtypes of breast cancer
    Nobuaki Matsubara
    Department of Oncology and Hematology, National Cancer Center Hospital East, 6 5 1 Kashiwanoha, Kashiwa City, Chiba 277 8577, Japan
    Breast Cancer Res Treat 137:203-12. 2013
    ..Pre-treatment Ki-67 and post-treatment Ki-67 were not independent prognostic factors in a multivariate analysis...
  13. doi request reprint Retrospective analysis of risk factors for central nervous system metastases in operable breast cancer: effects of biologic subtype and Ki67 overexpression on survival
    Mikiya Ishihara
    Divisions of Oncology Hematology, National Cancer Center Hospital East, Kashiwa, Japan mishihara clin medic mie u ac jp
    Oncology 84:135-40. 2013
    ..Identifying factors that predispose patients to central nervous system (CNS) metastases may hasten disease detection and improve treatment outcomes...
  14. doi request reprint Phase I and pharmacokinetic study of sorafenib, an oral multikinase inhibitor, in Japanese patients with advanced refractory solid tumors
    Hironobu Minami
    Oncology Hematology, National Cancer Center Hospital East, 6 5 1 Kashiwanoha, Kashiwa, Chiba, 277 8577, Japan
    Cancer Sci 99:1492-8. 2008
    ..In conclusion, sorafenib 400 mg bid was well tolerated in Japanese patients with advanced refractory solid tumors. The recommended dose for future clinical trials is 400 mg bid...
  15. doi request reprint Long-term outcome of pleurodesis with OK-432 in metastatic breast cancer: a new risk model for success from an analysis of 75 cases
    Nobuaki Matsubara
    Division of Oncology and Hematology, National Cancer Center Hospital East, 6 5 1 Kashiwanoha, Kashiwa, Chiba 277 8577, Japan
    Int J Clin Oncol 17:470-6. 2012
    ..However, the long-term outcome of pleurodesis and factors affecting successful pleurodesis have not been clarified...
  16. doi request reprint Effect of axitinib (AG-013736) on fatigue, thyroid-stimulating hormone, and biomarkers: a phase I study in Japanese patients
    Toru Mukohara
    National Cancer Center Hospital East, Oncology Hematology, Kashiwa, Japan
    Cancer Sci 101:963-8. 2010
    ..Axitinib 5 mg twice-daily is the recommended starting dose for Japanese patients. This trial is registered with ClinicalTrials.gov, identifier NCT00447005...
  17. doi request reprint Cardiac safety of trastuzumab as adjuvant treatment for Japanese patients with early breast cancer
    Mikiya Ishihara
    Division of Oncology Hematology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan
    Int J Clin Oncol 14:431-5. 2009
    ..Safety information on adjuvant trastuzumab use in Japanese patients, especially cardiac toxicity data, is needed...
  18. doi request reprint Final results of a safety and efficacy trial of preoperative sequential chemoradiation therapy for the nonsurgical treatment of early breast cancer: Japan Clinical Oncology Group Study JCOG0306
    Hirofumi Mukai
    National Cancer Center Hospital East, Chiba, Japan
    Oncology 85:336-41. 2013
    ..To explore the possibility of nonsurgical treatment of primary breast cancers by a sequential treatment of chemotherapy and radiotherapy...
  19. doi request reprint Prognostic impact of Ki-67 overexpression in subgroups categorized according to St. Gallen with early stage breast cancer
    Nobuaki Matsubara
    Department of Oncology and Hematology, National Cancer Center Hospital East, Chiba, Japan
    Oncology 81:345-52. 2011
    ..Ki-67 overexpression has been reported to be related to a poor prognosis for early stage breast cancer. We analyzed whether Ki-67 has a prognostic impact on risk subgroups based on the recommendations at St. Gallen in 2007...
  20. doi request reprint Review of primary unknown cancer: cases referred to the National Cancer Center Hospital East
    Nobuaki Matsubara
    Division of Oncology and Hematology, National Cancer Center Hospital East, 6 5 1 Kashiwanoha, Kashiwa, Chiba 277 8577, Japan
    Int J Clin Oncol 15:578-82. 2010
    ..We analyzed cases that were referred to the National Cancer Center Hospital East with preliminary diagnosed PUC to evaluate the natural history and clinical features...
  21. doi request reprint Elderly breast cancer therapy: a Japanese experience
    Yoichi Naito
    Division of Oncology and Hematology, National Cancer Center Hospital East, 6 5 1 Kashiwanoha, Kashiwa, Chiba 277 8577, Japan
    Jpn J Clin Oncol 40:717-21. 2010
    ..However, there seems to be a substantial undertreatment in the elderly...
  22. ncbi request reprint [Clinical diagnosis of primary unknown cancer-the present situation and problems]
    Hirofumi Mukai
    Division of Chemotherapy, National Cancer Center Hospital East, Japan
    Gan To Kagaku Ryoho 36:915-7. 2009
    ..There is not enough evidence on the utility of FDG-PTT or FDG-PET/CT for patients with PUC. Diagnosis of PUC should be made within one month from a patient's first visit to a hospital...
  23. ncbi request reprint Unknown primary carcinoma: a feasibility assessment of combination chemotherapy with cisplatin and docetaxel
    Hirofumi Mukai
    Department of Medical Oncology, National Cancer Center Hospital, 5 5 1 Tsukiji, Chuo Ku, Tokyo 104 0045, Japan
    Int J Clin Oncol 8:23-5. 2003
    ..We examined the feasibility of using a combination of docetaxel and cisplatin for the treatment of unknown primary carcinoma in order to prepare a larger scale prospective study...
  24. doi request reprint Comparison between neoadjuvant and adjuvant gemcitabine plus cisplatin chemotherapy for muscle-invasive bladder cancer
    Nobuaki Matsubara
    Division of Oncology and Hematology, National Cancer Center Hospital East, Chiba, Japan
    Asia Pac J Clin Oncol 9:310-7. 2013
    ..In this study we have compared the clinical outcomes between neoadjuvant and adjuvant chemotherapy in patients receiving GC...
  25. ncbi request reprint [Clinical evaluation of anti-cancer or targeted drugs and the optimal timing for changing therapeutics-breast cancer]
    Hirofumi Mukai
    Division of Oncology and Hematology, National Cancer Center Hospital East, Chiwa, Japan
    Gan To Kagaku Ryoho 39:1458-61. 2012
    ..The clinical evaluation of cancer therapeutics should be performed with clinical information, and the RECIST guideline can be flexibly adapted...
  26. ncbi request reprint Prospective study of positron emission tomography for evaluation of the activity of lapatinib, a dual inhibitor of the ErbB1 and ErbB2 tyrosine kinases, in patients with advanced tumors
    Kenji Kawada
    Department of Oncology Hematology, National Cancer Center Hospital East, Kashiwa, Japan
    Jpn J Clin Oncol 37:44-8. 2007
    ....
  27. doi request reprint E-cadherin expression on human carcinoma cell affects trastuzumab-mediated antibody-dependent cellular cytotoxicity through killer cell lectin-like receptor G1 on natural killer cells
    Chisako Yamauchi
    Pathology Division, Research Center for Innovative Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan
    Int J Cancer 128:2125-37. 2011
    ....
  28. ncbi request reprint The outpatient management of low-risk febrile patients with neutropenia: risk assessment over the telephone
    Toshiro Mizuno
    Division of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan
    Support Care Cancer 15:287-91. 2007
    ..The purpose of this retrospective study is to evaluate the feasibility of the risk assessment over the telephone in the outpatient management of low-risk febrile patients with neutropenia...
  29. ncbi request reprint [Management of toxicity associated with chemotherapy for breast cancer]
    Toru Mukohara
    Division of Hematology Oncology, National Cancer Center Hospital East
    Nihon Rinsho 65:516-22. 2007
  30. ncbi request reprint Genetic polymorphisms of CYP2B6 affect the pharmacokinetics/pharmacodynamics of cyclophosphamide in Japanese cancer patients
    Miki Nakajima
    Drug Metabolism and Toxicology, Division of Pharmaceutical Sciences, Graduate School of Medical Science, Kanazawa University, Kakuma machi, Kanazawa 920 1192, Japan
    Pharmacogenet Genomics 17:431-45. 2007
    ..To evaluate the effects of genetic polymorphisms of drug metabolizing enzymes on the pharmacokinetics of cyclophosphamide and its active metabolite, 4-hydroxycyclophosphamide, and on the pharmacodynamics...
  31. ncbi request reprint [Treatment guidelines for systemic adjuvant therapy of breast cancer]
    Toru Watanabe
    Hamamatsu Oncology Center Clinic
    Nihon Rinsho 64:419-23. 2006
    ..Guidelines that have authority in the adjuvant treatment of breast cancer are the NIH and NCCN guidelines, those developed in St. Gallen and those by Japan Breast Cancer Society...
  32. doi request reprint Histopathological criteria for assessment of therapeutic response in breast cancer (2007 version)
    Masafumi Kurosumi
    Department of Pathology, Saitama Cancer Center, Saitama, Japan
    Breast Cancer 15:5-7. 2008
  33. ncbi request reprint [Genetic testing for effective Herceptin therapy]
    Toru Watanabe
    Department of Medical Oncology, National Cancer Center Hospital
    Nihon Rinsho 60:603-11. 2002
    ..The experience gained in the testing of Herceptin has provided important lessons for the future testing of molecularly targeted compounds...